AstraZeneca PLC (AZNCF)
OTCMKTS
· Delayed Price · Currency is USD
125.50
+0.80 (0.64%)
Nov 21, 2024, 12:06 PM EST
AstraZeneca Revenue
AstraZeneca had revenue of $13.57B in the quarter ending September 30, 2024, with 18.04% growth. This brings the company's revenue in the last twelve months to $51.21B, up 13.81% year-over-year. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
51.21B
Revenue Growth
+13.81%
P/S Ratio
n/a
Revenue / Employee
569.59K
Employees
89,900
Market Cap
196.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.69B |
Ryman Healthcare Limited | 411.39M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
AstraZeneca News
- 1 day ago - AstraZeneca PLC (AZN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - Accesswire
- 1 day ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN - Accesswire
- 1 day ago - AstraZeneca PLC Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - AZN - Accesswire
- 1 day ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN - Accesswire
- 1 day ago - AstraZeneca raised to neutral at UBS despite China headwinds - Seeking Alpha
- 1 day ago - This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
- 1 day ago - AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US - Business Wire
- 1 day ago - Levi & Korsinsky Reminds Shareholders of an Investigation into AstraZeneca PLC (AZN) Regarding Potential Securities Fraud Allegations - Accesswire